The blue-chip CSI300 index edged down 0.1 per cent to 5,083.10, while the Shanghai Composite Index ended flat at 3,530.26 points.
Shenzhen’s start-up board declined 1.8 per cent, while Shanghai’s tech-focused lost 2.7 per cent.
Leading the declines among sectors, the CSI300 healthcare index tumbled as much as 6 per cent before ending 3.8 per cent lower.
Hangzhou Tigermed Consulting Co Ltd, Shanghai Fosun Pharmaceutical Group Co Ltd, Aier Eye Hospital Group Co Ltd , Beijing Tongrentang Co Ltd, and Wuxi AppTec Co Ltd retreated between 5 per cent and 10.9 per cent.
“The growth rates of many healthcare firms could not support their current high valuations,” Yan Kaiwen, an analyst with China Fortune Securities said.
Yan said some investors shifted to cheaper sectors with stable growth, including developers.
The CSI300 real-estate index climbed 2.9 per cent, with bellwether Vanke up 2.8 per cent.
Around the region, MSCI’s Asia ex-Japan stock index was firmer by 0.08 per cent, while Japan’s Nikkei index closed up 0.16 per cent.
At 0713 GMT, the yuan was quoted at 6.4612 per U.S. dollar, 0.04 per cent firmer than the previous close of 6.4639.
As of 0714 GMT, China’s A-shares were trading at a premium of 39.50 per cent over the Hong Kong-listed H-shares.
